Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein (original) (raw)
In Vivo Retargeting of Adenovirus Type 5 to v 6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery
Lynda Coughlan, Iain McNeish
Journal of Virology, 2009
View PDFchevron_right
Role of Adenoviruses in Cancer Therapy
SINTAYEHU TSEHA
Frontiers in Oncology
View PDFchevron_right
Targeting Adenoviral Entry to Enhance Oncolytic Antitumor Response
Hidde Haisma
The Open Gene Therapy Journal, 2013
View PDFchevron_right
Adenovirus Tumor Targeting and Hepatic Untargeting by a Coxsackie/Adenovirus Receptor Ectodomain Anti–Carcinoembryonic Antigen Bispecific Adapter
hua-jung Li
Cancer Research, 2007
View PDFchevron_right
Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents
Joshua Del Papa
Viruses, 2017
View PDFchevron_right
Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic
Joshua Del Papa
Cancer Gene Therapy, 2020
View PDFchevron_right
In Vivo Retargeting of Adenovirus Type 5 to αvβ6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery
ANTONIO SAHA
Journal of Virology, 2009
View PDFchevron_right
Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Stuart Nicklin
Current Gene Therapy, 2004
View PDFchevron_right
Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11
Yaohe Wang
Molecular Therapy, 2012
View PDFchevron_right
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
James Davies
Viruses, 2015
View PDFchevron_right
Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy
Nayara Tessarollo
Cancers, 2021
View PDFchevron_right
Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control
Maarit Suomalainen
Nature Communications
View PDFchevron_right
Advances in adenoviral vectors for cancer gene therapy
Juan Carlos Huamani Contreras
Expert Opinion on Therapeutic Patents, 1997
View PDFchevron_right
Replacement of Native Adenovirus Receptor-Binding Sites with a New Attachment Moiety Diminishes Hepatic Tropism and Enhances Bioavailability in Mice
Victor Van Beusechem
Human Gene Therapy, 2008
View PDFchevron_right
Modified adenoviruses for cancer gene therapy
Anna Kanerva
International journal of cancer. Journal international du cancer, 2004
View PDFchevron_right
Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells
Buck Rogers
Journal of Virology, 2000
View PDFchevron_right
Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach
Etienne Régulier
Cancer Gene Therapy, 2000
View PDFchevron_right
Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors
Tanja Hansen
Cancers, 2022
View PDFchevron_right
Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors
Hidde Haisma
Gene Therapy, 2003
View PDFchevron_right
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Masoud Najafi
View PDFchevron_right
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule
Ramon Alemany
Cancer research, 2001
View PDFchevron_right
Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment
Sari Pesonen
Gene Therapy, 2009
View PDFchevron_right
The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery
Lidia Kurochkina
Gene Therapy, 1997
View PDFchevron_right
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Terry Hermiston
Nature Medicine, 2000
View PDFchevron_right
Adenovirus i-Leader Truncation Bioselected Against Cancer-associated Fibroblasts to Overcome Tumor Stromal Barriers
Ramon Alemany
Molecular Therapy, 2012
View PDFchevron_right
Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo
tiejun zhao
Cancer research, 2003
View PDFchevron_right
Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells
Sacha Brigitte Geutskens
Gene Therapy, 2000
View PDFchevron_right
Antitumor Activity and Prolonged Expression from a TRAIL-Expressing Adenoviral Vector
Paulo Mendes
Neoplasia, 2002
View PDFchevron_right
A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy
Long Le, Joel Glasgow, J. Michael Mathis
View PDFchevron_right
Oncolytic adenoviruses – selective retargeting to tumor cells
J. Michael Mathis
Oncogene, 2005
View PDFchevron_right
Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency
Ramon Alemany, M. Cascallo, Sonia Guedan
Cancer Research, 2008
View PDFchevron_right
In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus
Buck Rogers
2002
View PDFchevron_right